Kyowa Hakko Kirin hit with a new PhIII setback on an old Parkinson’s drug
Eight years after Japan’s Kyowa Hakko Kirin was handed an FDA rejection for its Parkinson’s drug istradefylline (KW-6002), researchers say they recorded
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
